Molecular biomarkers in glaucoma

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 121-131

  Bhattacharya, Sanjoy K ^a   Lee, Richard K ^a   Grus, Franz H ^b   Bhattacharya, Sanjoy ^c   Grus, Franz ^c   Lee, Richard ^c   Beuerman, Roger ^c   Burlingame, Alma ^c   Coutinho, Antonio ^c   Crabb, John W ^c   Crowston, Jonathan ^c   Dodel, Richard ^c   Fingert, John ^c   Hauser, Michael A ^c   John, Simon ^c   Kaur, Inderjeet ^c   Martin, Keith ^c   Miller, Stephen ^c   Pandey, Akhilesh ^c   Pasquale, Louis R ^c   Pericak Vance, Margaret ^c   Petricoin, Emanuel ^c   Pfeiffer, Norbert ^c   Ritch, Robert ^c   Schmetterer, Leopold ^c   Tezel, Gülgün ^c   Topouzis, Fotis ^c   Viswanathan, Ananth ^c   Weinreb, Robert ^c   Wiggs, Janey L ^c   Zack, Donald ^c   Zhou, Yong ^c   Asai, Nobuharu ^c   Bell, Katharina ^c   Bitoun, Pierre ^c   Boatright, Jeffrey ^c   Boehm, Nils ^c   Bonakdar, Mojtaba ^c   Borras, Terete ^c   Cao, Jingtai ^c   Carper, Deborah ^c   Chin, Hemin ^c   Coca Prados, Miguel ^c   Dong, Cun Jian ^c   Faunce, Douglas ^c   Fautsch, Michael ^c   Flanagan, John ^c   Gong, Haiyan ^c   Gonzalez, Hector ^c   Grishanin, Ruslan ^c   Grosskreutz, Cynthia ^c   Grunden, John ^c   Hong, Samin ^c   Hood, Donald ^c   Ju, Won Kyu ^c   Junk, Anna ^c   Kang, Kui Dong ^c   Karl, Mike ^c   Kaufman, Herbert ^c   Kaufman, Paul ^c   Khaw, Peng ^c   Kim, In Beom ^c   Kirihara, Tomoko ^c   Komaromy, Andras ^c   Kramann, Christina ^c   Liebmann, Jeffrey ^c   Lindsey, James ^c   Lorenz, Katrin ^c   Mackey, David ^c   Markabi, Sabri ^c   Mest, Mallory ^c   Miller, Robert ^c   Moroi, Sayoko ^c   O’Brien, Joan ^c   O’Brien, Colm ^c   Parikh, Toral ^c   Park, Sung Chul ^c   Pe’er, Jacob ^c   Petrash, J Mark ^c   Qu, Juan ^c   Rittenhouse, Kay ^c   Roberds, Steven ^c   Sharif, Naj ^c   Shepard, Allan ^c   Sui, Ruifang ^c   Toris, Carol ^c   Traverso, Carlo ^c   Valorie, Tracy ^c   Weinmann, Roberto ^c   Wheeler, Larry ^c   Whitlock, Andy ^c   Wirostko, Barbara ^c   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPITOPE; MYOCILIN; OPTINEURIN;

ACCURACY; ARTICLE; CENTRAL CORNEAL THICKNESS; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENOMICS; GENOTYPE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; PSEUDOEXFOLIATION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; TRANSCRIPTOMICS; CONFERENCE PAPER; GENETIC MARKER; GENETICS; METABOLISM; METABOLOME; PHYSIOLOGY;

BIOLOGICAL MARKERS; GENETIC MARKERS; GENOMICS; GLAUCOMA; HUMANS; METABOLOME; PROTEOMICS;

MLCS; MLOWN;

EID: 84874693678     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11067     Document Type: Article

References (119)

1. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature. 2003;425:905.
2. Liotta LA, Petricoin E. Cancer biomarkers: closer to delivering on their promise. Cancer Cell. 2011;20:279-280.
3. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA. 2001;286:2211-2214.
4. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845-867.
5. Wildes D, Wells JA. Sampling the N-terminal proteome of human blood. Proc Natl Acad Sci U S A. 2010;107:4561-4566.
6. Wulfkuhle JD, Speer R, Pierobon M, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 2008;7:1508-1517.
7. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20:1981-1989.
8. Tamburro D, Fredolini C, Espina V, et al. Multifunctional coreshell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc. 2011;133:19178-19188.
9. Luchini A, Fredolini C, Espina BH, et al. Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. Curr Mol Med. 2010;10:133-141.
10. Rapkiewicz A, Espina V, Zujewski JA, et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer. 2007; 111:173-184.
11. Davuluri G, Espina V, Petricoin EF III, et al. Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch Ophthalmol. 2009;127:613-621.
12. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377:1019-1031.
13. Callesen AK, Mogensen O, Jensen AK, et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: a systematic review. J Proteomics. 2012;75:2758-2772.
14. Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. Proteomics. 2012;12:722-735.
15. Ni J, Yuan X, Gu J, et al. Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics. 2009;8:1921-1933.
16. Gu J, Pauer GJ, Yue X, et al. Assessing susceptibility to agerelated macular degeneration with proteomic and genomic biomarkers. Mol Cell Proteomics. 2009;8:1338-1349.
17. Yuan X, Gu X, Crabb JS, et al. Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics. 2010;9:1031-1046.
18. Zhou L, Beuerman RW. Tear analysis in ocular surface diseases. Prog Retin Eye Res. 2012;31:527-550.
19. Prakash A, Rezai T, Krastins B, et al. Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J Proteome Res. 2012;11:3986-3995.
20. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics. 2010;9:184-196.
21. Knepper PA, Samples JR, Yue BYJT. Biomarkers of primary open-angle glaucoma. Expert Review of Ophthalmology. 2010;5:731-742.
22. Allingham RR, Wiggs JL, Hauser ER, et al. Early adult-onset POAG linked to 15q11-13 using ordered subset analysis. Invest Ophthalmol Vis Sci. 2005;46:2002-2005.
23. Ramdas WD, van Koolwijk LM, Cree AJ, et al. Clinical implications of old and new genes for open-angle glaucoma. Ophthalmology. 2011;118:2389-2397.
24. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.
25. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308-1312.
26. Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007;317:1397-1400.
27. Challa P. Genetics of adult glaucoma. International Ophthalmology Clinics. 2011;51:37-51.
28. Macgregor S, Hewitt AW, Hysi PG, et al. Genome-wide association identifies ATOH7 as a major gene determining human optic disc size. Hum Mol Genet. 2010;19:2716-2724.
29. Ramdas WD, van Koolwijk LM, Ikram MK, et al. A genomewide association study of optic disc parameters. PLoS Genet. 2010;6:e1000978.
30. van Koolwijk LM, Ramdas WD, Ikram MK, et al. Common genetic determinants of intraocular pressure and primary open-angle glaucoma. PLoS Genet. 2012;8:e1002611.
31. Lu Y, Dimasi DP, Hysi PG, et al. Common genetic variants near the Brittle Cornea Syndrome locus ZNF469 influence the blinding disease risk factor central corneal thickness. PLoS Genet. 2010;6:e1000947.
32. Burdon KP, Macgregor S, Hewitt AW, et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet. 2011;43: 574-578.
33. Fan BJ, Wang DY, Pasquale LR, Haines JL, Wiggs JL. Genetic variants associated with optic nerve vertical cup-to-disc ratio are risk factors for primary open angle glaucoma in a US Caucasian population. Invest Ophthalmol Vis Sci. 2011;52: 1788-1792.
34. Wiggs J, Yaspan B, Hauser M, et al. Common variants in the CDKN2BAS region on 9p21 and a novel region on 8q23 are associated with the normal tension form of open-angle glaucoma with increased susceptibility to optic nerve degeneration. PLoS Genet. 2012. In press.
35. Berdahl JP, Allingham R, Johnson DH. Cerebrospinal fluid pressure in primary open angle glaucoma. Ophthalmology. 2008;115:763-768.
36. Ren R, Wang N, Zhang X, Cui T, Jonas JB. Trans-lamina cribrosa pressure difference correlated with neuroretinal rim area in glaucoma. Graefes Arch Clin Exp Ophthalmol. 2011; 249:1057-1063.
37. Nakano M, Ikeda Y, Tokuda Y, et al. Common variants in CDKN2B-AS1 associated with optic nerve vulnerability of glaucoma identified by genome-wide association studies in Japanese. PLoS One. 2012;7:e33389.
38. Osman W, Low SK, Takahashi A, Kubo M, Nakamura Y. A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. Hum Mol Genet. 2012;21:2836-2842.
39. Cao D, Jiao X, Liu X, et al. CDKN2B polymorphism is associated with primary open-angle glaucoma (POAG) in the Afro-Caribbean population of Barbados, West Indies. PLoS One. 2012;7:e39278.
40. Burdon KP, Crawford A, Casson RJ, et al. Glaucoma risk alleles at CDKN2B-AS1 are associated with lower intraocular pressure, normal-tension glaucoma, and advanced glaucoma. Ophthalmology. 2012;119:1539-1545.
41. Ramdas WD, van Koolwijk LM, Lemij HG, et al. Common genetic variants associated with open-angle glaucoma. Hum Mol Genet. 2011;20:2464-2471.
42. Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet. 2010;42:906-909.
43. Wiggs JL, Hee Kang J, Yaspan BL, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in Caucasians from the USA. Hum Mol Genet. 2011;20:4707-4713.
44. Surgucheva I, Surguchov A. Expression of caveolin in trabecular meshwork cells and its possible implication in pathogenesis of primary open angle glaucoma. Mol Vis. 2011; 17:2878-2888.
45. Williams TM, Lisanti MP. The Caveolin genes: from cell biology to medicine. Ann Med. 2004;36:584-595.
46. Kang JH, Wiggs JL, Rosner BA, et al. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with gender and postmenopausal hormone use. Invest Ophthalmol Vis Sci. 2010;51:971-979.
47. Zode GS, Bugge KE, Mohan K, et al. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2012;53:1557-1565.
48. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641-1648.
49. Leibovitch I, Kurtz S, Kesler A, Feithliher N, Shemesh G, Sela BA. C-reactive protein levels in normal tension glaucoma. J Glaucoma. 2005;14:384-386.
50. Sugiyama T, Moriya S, Oku H, Azuma I. Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv Ophthalmol. 1995;39(suppl 1): S49-56.
51. Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol. 2003; 48(suppl 1):S25-37.
52. Wong TT, Zhou L, Li J, et al. Proteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glaucoma medication. Invest Ophthalmol Vis Sci. 2011;52:7385-7391.
53. Boehm N, Wolters D, Thiel U, et al. New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study. Brain Behav Immun. 2012;26:96-102.
54. Bollinger KE, Crabb JS, Yuan X, Putliwala T, Clark AF, Crabb JW. Quantitative proteomics: TGFb2 signaling in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52:8287-8294.
55. Crabb JW, Yuan X, Dvoriantchikova G, Ivanov D, Crabb JS, Shestopalov VI. Preliminary quantitative proteomic characterization of glaucomatous rat retinal ganglion cells. Exp Eye Res. 2010;91:107-110.
56. Bollinger K, Crabb J, Yuan X, Putliwala T, Clark A, Crabb J. Proteomic similarities in steroid responsiveness in normal and glaucomatous trabecular meshwork cells. Mol Vision. 2012. In press.
57. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004;3: 1154-1169.
58. Ishihama Y, Oda Y, Tabata T, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005;4:1265-1272.
59. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11:O111.016717.
60. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 2007;6:2212-2229.
61. Qin S, Zhou Y, Lok AS, et al. SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics. 2012;12:1244-1252.
62. Yang K, Cheng H, Gross RW, Han X. Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics. Anal Chem. 2009; 81:4356-4368.
63. Schuhmann K, Herzog R, Schwudke D, Metelmann-Strupat W, Bornstein SR, Shevchenko A. Bottom-up shotgun lipidomics by higher energy collisional dissociation on LTQ Orbitrap mass spectrometers. Anal Chem. 2011;83: 5480-5487.
64. Herzog R, Schwudke D, Schuhmann K, et al. A novel informatics concept for high-throughput shotgun lipidomics based on the molecular fragmentation query language. Genome Biol. 2011;12:R8.
65. Haldane AG, May RM. Systemic risk in banking ecosystems. Nature. 2011;469:351-355.
66. Wax MB. Is there a role for the immune system in glaucomatous optic neuropathy? Curr Opin Ophthalmol. 2000;11:145-150.
67. Tezel G, Seigel GM, Wax MB. Autoantibodies to small heat shock proteins in glaucoma. Invest Ophthalmol Vis Sci. 1998;39:2277-2287.
68. Grus FH, Joachim SC, Hoffmann EM, Pfeiffer N. Complex autoantibody repertoires in patients with glaucoma. Mol Vis. 2004;10:132-137.
69. Tezel G, Wax MB. Glaucoma. Chem Immunol Allergy. 2007; 92:221-227.
70. Grus FH, Joachim SC, Wuenschig D, Rieck J. Autoimmunity and glaucoma. J Glaucoma. 2008;17:79-84.
71. Grus FH, Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Wax MB. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest Ophthalmol Vis Sci. 2006;47:968-976.
72. Joachim SC, Pfeiffer N, Grus FH. Autoantibodies in patients with glaucoma: a comparison of IgG serum antibodies against retinal, optic nerve, and optic nerve head antigens. Graefes Arch Clin Exp Ophthalmol. 2005;243:817-823.
73. Poletaev A, Osipenko L. General network of natural autoantibodies as immunological homunculus (Immunculus). Autoimmun Rev. 2003;2:264-271.
74. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812-818.
75. Li WH, Zhao J, Li HY, et al. Proteomics-based identification of autoantibodies in the sera of healthy Chinese individuals from Beijing. Proteomics. 2006;6:4781-4789.
76. Avrameas S. Natural autoantibodies: from "horror autotoxicus" to "gnothi seauton." Immunol Today. 1991;12:154-159.
77. Nobrega A, Haury M, Grandien A, Malanchere E, Sundblad A, Coutinho A. Global analysis of antibody repertoires. II. Evidence for specificity, self-selection and the immunological "homunculus" of antibodies in normal serum. Eur J Immunol. 1993;23:2851-2859.
78. George J, Gilburd B, Shoenfeld Y. The emerging concept of pathogenic natural autoantibodies. Hum Antibodies. 1997;8: 70-75.
79. Terzoglou AG, Routsias JG, Avrameas S, Moutsopoulos HM, Tzioufas AG. Preferential recognition of the phosphorylated major linear B-cell epitope of La/SSB 349-368 aa by anti-La/ SSB autoantibodies from patients with systemic autoimmune diseases. Clin Exp Immunol. 2006;144:432-439.
80. Graus YM, De Baets MH. Myasthenia gravis: an autoimmune response against the acetylcholine receptor. Immunol Res. 1993;12:78-100.
81. Hughes BW, Moro De Casillas ML, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol. 2004;24:21-30.
82. Dodel R, Neff F, Noelker C, et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs. 2010;70:513-528.
83. Dodel R, Balakrishnan K, Keyvani K, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci. 2011;31:5847-5854.
84. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30:1728-1736.
85. Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol. 2009;158(suppl 1): 34-42.
86. Janciauskiene S, Westin K, Grip O, Krakau T. Detection of Alzheimer peptides and chemokines in the aqueous humor. Eur J Ophthalmol. 2011;21:104-111.
87. Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid(1-42) and tau in patients with retinal diseases. Jpn J Ophthalmol. 2005; 49:106-108.
88. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A. 2007;104: 13444-13449.
89. Grus FH, Joachim SC, Pfeiffer N. Analysis of complex autoantibody repertoires by surface-enhanced laser desorption/ ionization-time of flight mass spectrometry. Proteomics. 2003;3:957-961.
90. Boehm N, Wolters D, Thiel U, et al. New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study. Brain Behav Immun. 2011;26:96-102.
91. Wax MB, Tezel G, Yang J, et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci. 2008;28:12085-12096.
92. Joachim SC, Grus FH, Kraft D, et al. Complex antibody profile changes in an experimental autoimmune glaucoma animal model. Invest Ophthalmol Vis Sci. 2009;50:4734-4742.
93. Joachim SC, Wax MB, Seidel P, Pfeiffer N, Grus FH. Enhanced characterization of serum autoantibody reactivity following HSP 60 immunization in a rat model of experimental autoimmune glaucoma. Curr Eye Res. 2010; 35:900-908.
94. Gramlich OW, Joachim SC, Gottschling PF, et al. Ophthalmopathology in rats with MBP-induced experimental autoimmune encephalomyelitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:1009-1020.
95. Bell K, Funke S, Pfeiffer N, Grus FH. Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells. PLoS One. 2012;7:e46910.
96. Shmerling RH. Autoantibodies in systemic lupus erythematosus-there before you know it. N Engl J Med. 2003;349: 1499-1500.
97. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-1533.
98. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
99. Albon J, Purslow PP, Karwatowski WS, Easty DL. Age related compliance of the lamina cribrosa in human eyes. Br J Ophthalmol. 2000;84:318-323.
100. Albon J, Karwatowski WS, Easty DL, Sims TJ, Duance VC. Age related changes in the non-collagenous components of the extracellular matrix of the human lamina cribrosa. Br J Ophthalmol. 2000;84:311-317.
101. Harris A, Ciulla TA, Chung HS, Martin B. Regulation of retinal and optic nerve blood flow. Arch Ophthalmol. 1998;116: 1491-1495.
102. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J Glaucoma. 2009;18:93-100.
103. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298-300.
104. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006;25:490-513.
105. Trounce I, Byrne E, Marzuki S. Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing. Lancet. 1989;1:637-639.
106. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2533-2541.
107. Abu-Amero KK, Morales J, Osman MN, Bosley TM. Nuclear and mitochondrial analysis of patients with primary angleclosure glaucoma. Invest Ophthalmol Vis Sci. 2007;48:5591-5596.
108. Lee S, Sheck L, Crowston JG, et al. Impaired complex-I-linked respiration and ATP synthesis in primary open-angle glaucoma patient lymphoblasts. Invest Ophthalmol Vis Sci. 2012; 53:2431-2437.
109. Kasahara T, Kubota M, Miyauchi T, et al. Mice with neuronspecific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry. 2006;11: 577-593, 523.
110. Kong YX, Van Bergen N, Trounce IA, et al. Increase in mitochondrial DNA mutations impairs retinal function and renders the retina vulnerable to injury. Aging Cell. 2011;10: 572-583.
111. Rance G, O'Hare F, O'Leary S, et al. Auditory processing deficits in individuals with primary open-angle glaucoma. Int J Audiol. 2012;51:10-15.
112. Tezel G, Yang X, Luo C, et al. Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci. 2010;51:5071-5082.
113. Luo C, Yang X, Kain AD, Powell DW, Kuehn MH, Tezel G. Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling. Invest Ophthalmol Vis Sci. 2010;51:5697-5707.
114. Tezel G. The immune response in glaucoma: a perspective on the roles of oxidative stress. Exp Eye Res. 2011;93:178-186.
115. Vanderlugt CL, Miller SD. Epitope spreading in immunemediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2:85-95.
116. Higashide T, Kawaguchi I, Ohkubo S, Takeda H, Sugiyama K. In vivo imaging and counting of rat retinal ganglion cells using a scanning laser ophthalmoscope. Invest Ophthalmol Vis Sci. 2006;47:2943-2950.
117. Cordeiro MF, Guo L, Luong V, et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci U S A. 2004;101:13352-13356.
118. Printz C. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. Cancer. 2010;116:3307-3308.
119. Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment. Nat Rev Drug Discov. 2010;9:423.